Category Archives: Stem Cell Therapy

Stem Cell Therapy | Genetics and Rheumatoid Arthritis
What do genes have to do with arthritis? No... not those kinds of genes... these kinds of jeans. Genetics can explain why infections can trigger rheumatoid arthritis Appearing in Science Codex...

By: Nathan Wei

See more here:
Stem Cell Therapy | Genetics and Rheumatoid Arthritis - Video

Stem cell therapy | safety of stem cells
http://www.arthritistreatmentcenter.com So... are stem cells really safe? The answer next... Safety Of Autologous Adipose Tissue-derived Stem Cells With Platelet-rich plasma Into Human Articular...

By: Nathan Wei

See the rest here:
Stem cell therapy | safety of stem cells - Video

Stamina risks range from nausea to cancer, prosecutors say

(ANSA) - Turin, April 24 - Between 20% and 25% of Italian patients treated with a recently discredited stem-cell therapy called Stamina experienced "adverse effects", medical consultants said in a report submitted to prosecutors in Turin on Thursday. Such effects, said the report, had not been reported to health officials. Earlier Thursday, Turin investigators submitted a report that said risks of the treatment range from nausea to cancer. Prosecutors concluded a probe Wednesday of 20 suspects involved in the Stamina treatment, including Davide Vannoni, founder of the Stamina Foundation, who may face indictment. Charges could include criminal association to commit aggravated fraud and administration of dangerous drugs, according to prosecutors whose probe examined the treatment of slightly more than 100 patients. Another 37 donors of stem cells used in the controversial treatment, rejected by the health ministry, were examined during the investigation. According to prosecutors, Vannoni and other suspects "pretended" that there was a "high chance" of recovery from serious illness if patients agreed to the Stamina treatment. Earlier this month, hospitals in Italy that used the discredited stem-cell treatment announced they had suspended the program. That followed announcements last fall by Italy's health ministry that the Stamina Foundation - the nonprofit foundation that developed the treatment - would not be allowed to test it on humans. The foundation was also stripped of its non-profit status after a study found its treatment was "ignorant of stem-cell biology".

See the article here:
Stemcell therapy 'adversely effected' 2025% of patients

PUBLIC RELEASE DATE:

23-Apr-2014

Contact: Robert Miranda cogcomm@aol.com Cell Transplantation Center of Excellence for Aging and Brain Repair

Putnam Valley, NY. (Apr. 23 2014) A team of researchers in Korea who transplanted human neural stem cells (hNSCs) into the brains of nonhuman primates and assessed cell survival and differentiation after 22 and 24 months found that the hNSCs had differentiated into neurons at 24 months and did not cause tumors.

The study will be published in a future issue of Cell Transplantation but is currently freely available on-line as an unedited early e-pub at: http://www.ingentaconnect.com/content/cog/ct/pre-prints/content-ct1117Antonucci2.

The hNSCs were labeled with magnetic nanoparticles to enable them to be followed by magnetic resonance imaging (MRI). They did not use immunosuppressants. According to the researchers, their study is the first to evaluate and show the long-term survival and differentiation of hNSCs without the need for immunosuppression.

The researchers concluded that hNSCs could be of "great value" as a source for cell replacement and gene transfer for the treatment of Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), spinal cord injury and stroke.

"Stroke is the fourth major cause of death in the US behind heart failure, cancer, and lower respiratory disease," said study co-author Dr. Seung U. Kim of University of British Columbia Hospital's department of neurology in Canada. "While tissue plasminogen activator (tPA) treatment within three hours after a stroke has shown good outcomes, stem cell therapy has the potential to address the treatment needs of those stroke patients for whom tPA treatment was unavailable or did not help."

Dr. Kim and colleagues in Korea grafted magnetic particle-labeled hNSCs into the brains of laboratory primates and evaluated their performance to assess their survival and differentiation over 24 months. Of particular interest was determining their ability to differentiate into neurons and to determine whether the cells caused tumorogenesis.

"We injected hNSCs into the frontal lobe and the putamen of the monkey brain because they are included in the middle cerebral artery (MCA) territory, which is the main target in the development of the ischemic lesion in animal stroke models," commented Dr. Kim. "Thus, research on survival and differentiation of hNSCs in the MCA territory should provide more meaningful information to cell transplantation in the MCA occlusion stroke model."

View original post here:
Study finds long-term survival of human neural stem cells transplanted into primate brain

Tuesday, April 22 11:57:06

Orbsen Therapeutics, a spin-out from NUI Galway's Regenerative Medicine Institute (REMEDI), is to partner with the University of Birmingham in a E6 million EU FP7 funded MERLIN project to fight liver disease.

The EU FP7-funded project known by the acronym "MERLIN" (MEsynchymal stem cells to Reduce Liver INflammation) is led by Professor Phil Newsome, Clinical Director of the Birmingham University Stem Cell Centre. MERLIN will advance Orbsen's proprietary cell therapy to a Phase 2a clinical trial in patients with inflammatory liver disease. This MERLIN project will evaluate the Orbsen cell therapy in 4 different research laboratories across Europe and the project will culminate in a Phase 2a clinical trial of the therapy in the crippling inflammatory liver disease, Primary Sclerosing Cholangitis.

This is Orbsen's fourth success in attracting FP7 funding (the EU's Seventh Framework Programme for Research), making them one of Ireland's most successful private companies in this funding programme and now connects Orbsen to 23 global collaborators. Other successful cell therapy projects for Orbsen include PURSTEM (completed), REDDSTAR (ongoing) and DeCIDE (ongoing).

Orbsen Therapeutics Ltd. is a privately-held company founded in 2006 as a spin-out from Ireland's Regenerative Medicine Institute (REMEDI) in NUI Galway. As part of the PurStem EU FP7 program, Orbsen developed proprietary technologies that enable the prospective purification of highly defined and therapeutic (stromal) cells from several human tissues, including bone marrow, adipose tissue and umbilical cord.

Orbsen's CEO Brian Molloy said, "Orbsen has secured substantial amounts of research funding in the last 18 months which will further validate our product and bring us through to a "first in man" clinical trial in 2015/16. Our model has always focused on putting the 'science first' and we have successfully used that approach to develop a technology that could potentially position us and indeed Ireland at the leading edge of European Cell Therapy development."

Mr Molloy continued, "As a spin-out from the NUI Galway based REMEDI Institute we have focused the majority of our collaborations with an Irish research team. Our success in the MERLIN project now demonstrates that we are capable of playing a key role in collaborations led by researchers across Europe."

The total research budget for the MERLIN project is close to E6 Million of which E1 Million will go directly to Orbsen Therapeutics over the 4-year period of the project.

Read the original:
Irish cell therapy firm in E6m research